Given our study’s findings, we propose that the adverse prognosis of IgA MM patients may be in part due to differences in disease management due to misclassification of disease response, or delayed detection of disease due to underestimation of tumor burden. This evidence concerns the gene CD79A and Miyoshi myopathy.